YEYasir Y. Elamin

Yasir Y. Elamin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yasir Y. Elamin has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Shereen Rafee

    Department of Medical Oncology, St James's Hospital, Dublin, Ireland

    2 shared publications
  • Bryan T. Hennessy

    Department of Medical Oncology, Royal College of Surgeons, Beaumont Hospital

    1 shared publication
  • Kathy Gately

    Thoracic Oncology Research Group, Trinity Translational Medicine Institute, Trinity College Dublin, St. James’s Hospital, D08 NHY1 Dublin, Ireland

    1 shared publication
  • Kenneth J. O′Byrne

    Department of Medical Oncology, St James's Hospital, Dublin, Ireland

    1 shared publication
  • Nemer Osman

    Department of Medical Oncology, St James's Hospital, Dublin, Ireland

    1 shared publication
  • Sinead Toomey

    Department of Medical Oncology, Royal College of Surgeons, Beaumont Hospital

    1 shared publication

Latest Publications

  • Thymidine Phosphorylase in Cancer; Enemy or Friend?

    by Yasir Y. Elamin, Shereen Rafee, Nemer Osman, Kenneth J. O′Byrne, Kathy Gately

    Thymidine phosphorylase (TP) is a nucleoside metabolism enzyme that plays an important role in the pyrimidine pathway.TP catalyzes the conversion of thymidine to thymine and 2-deoxy-α-D-ribose-1-phosphate (dRib-1-P). Although this reaction is reversible, the main metabolic function of TP is catabolic. TP is identical to the angiogenic factor platelet-derived endothelial-cell growth factor (PD-ECGF). TP is overexpressed in several human cancers in response to cellular stressful conditions like hypoxia, acidosis, chemotherapy and radiotherapy. TP has been shown to promote tumor angiogenesis, invasion, metastasis, evasion of the immune-response and resistance to apoptosis. Some of the biological effects of TP are dependent on its enzymatic activity, while others are mediated through cytokines like interleukin 10 (IL-10), basic fibroblast growth factor (bFGF) and tumour necrosis factor α (TNFα). Interestingly, TP also plays a role in cancer treatment through its role in the conversion of the oral fluoropyrimidine capecitabine into its active form 5-FU. TP is a predictive marker for fluoropyrimidine response. Given its various biological functions in cancer progression, TP is a promising target in cancer treatment. Further translational research is required in this area.


  • Immune Effects of Bevacizumab: Killing Two Birds with One Stone

    by Yasir Y. Elamin, Shereen Rafee, Sinead Toomey, Bryan T. Hennessy

    Angiogenesis or new vessel formation is essential for tumour growth and progression. Therefore, targeting angiogenesis has been an attractive strategy in the treatment ofcancer. Bevacizumab is a recombinant humanized monoclonal IgG1 antibody thattargets vascular endothelial growth factor-A (VEGF-A) - a key molecular player inangiogenesis. Bevacizumumab has shown clinical efficacy in phase III clinical trials inseveral advanced solid malignancies. The clinical efficacy of bevacizumumab isprimarily due to its antiangiogenic effects; however, there are direct antitumor effectsand immunomodulatory effects. Enhancing the immune system to restore itsantitumour activity has been utilized successfully in clinical setting. In this article we willdiscuss the possible immunomodulatory effects of the most clinically usedantiangiogenic agent; bevacizumumab.